Antares Pharma

Ewing, United States Founded: 2000 • Age: 26 yrs Acquired By Halozyme
Existing drugs are reformulated using proprietary pen injectors.
Annual revenue $184.0M Latest available
Total funding - 4 rounds
Employees - Tracked headcount
Investors 3 Known backers
Products 3 Services tracked
Competitors - Brand Intelligence

About Antares Pharma

Antares Pharma is a company based in Ewing (United States) founded in 2000 was acquired by Halozyme in April 2022. Antares Pharma offers products and services including ENHANZE, Auto-Injector, and Multi-Dose Pen.

  • Headquarter Ewing, United States
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Antares Pharma, Inc.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $183.98 M (USD)
    23
    as on Dec 31, 2021
  • Net Profit
    $46.29 M (USD)
    -18
    as on Dec 31, 2021
  • EBITDA
    $65.93 M (USD)
    384
    as on Dec 31, 2021
  • Latest Funding Round
    $2.75 M (USD), Post-IPO

    Mar 06, 2018

  • Investors
    Halozyme

    & 2 more

  • Employee Count
    Not available
  • Acquired by
    Halozyme

    (Apr 13, 2022)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Antares Pharma

Antares Pharma offers a comprehensive portfolio of products and services, including ENHANZE, Auto-Injector, and Multi-Dose Pen.

Product name locked
Category locked
Primary

Enhances drug administration for improved treatment efficacy.

Product name locked
Category locked
Locked

Facilitates self-injection of medications for patient convenience.

Product name locked
Category locked
Locked

Enables multiple doses in a single device for easier management.

People of Antares Pharma

Headcount 50-200
Employee Profiles 35
Board Members and Advisors 5
Employee Profiles
People
Peter Sadowski
SVP, Technology Portfolio & Intellectual Property
People
Michelle Sims
Clinical Specialist
People
Peter J. Graham
EVP, General Counsel, Human Resources, Chief Compliance Officer & Corporate Secretary
People
Robert F. Apple
President & CEO

Unlock access to complete

Board Members and Advisors
people
Anton Gueth
Director

Unlock access to complete

Funding Insights of Antares Pharma

Investors in Antares Pharma

Antares Pharma has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Halozyme, Hercules Capital and Ferring Pharmaceuticals.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture debt financing is provided to companies in multiple sectors.
Locked Locked Locked
Provider of drugs in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics
Locked Locked Locked
Drug delivery technologies for disease treatment are developed.
Locked Locked Locked
Premium access

Investor details for Antares Pharma

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Antares Pharma

Investments
Premium access

Investment portfolio details for Antares Pharma

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Antares Pharma

Premium access

Detailed financials for Antares Pharma

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Antares Pharma Comparisons

Antares Pharma Primary company
Description
Existing drugs are reformulated using proprietary pen inject...
Location
Ewing, United States
Founded Year
2000
Annual Revenue
$183.98 M (USD)
Net Profit
$46.29 M (USD)
EBITDA
$65.93 M (USD)
Employees
Not available
Premium access

Peer comparison for Antares Pharma

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Antares Pharma

Premium access

Detailed competitors of Antares Pharma

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Antares Pharma

Premium access

Complete news archive for Antares Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Antares Pharma

Antares Pharma was founded in 2000 and raised its 1st funding round 7 years after it was founded.

Antares Pharma is headquartered in Ewing, United States. It is registered at Ewing, New Jersey, United States.

Annual revenue of Antares Pharma is $183.98M as on Dec 31, 2021.

Antares Pharma was established in 2000 in Ewing, United States, within the pharmaceuticals sector focused on drug delivery systems. Existing medications are reformulated through the VIBEX platform, featuring pre-filled pen injectors for intradermal, subcutaneous, or intramuscular administration. Collaborations are formed with pharmaceutical partners to adapt their products. The development pipeline encompasses injectors for human growth hormone from Ferring, estradiol from Meda, Gelnique from Actavis, and methotrexate.

Antares Pharma offers ENHANZE, Auto-Injector, and Multi-Dose Pen.

Antares Pharma has 3 investors. Key investors include Halozyme, Hercules Capital, and Ferring Pharmaceuticals.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available